alexa Management of Ductal Carcinoma In situ
ISSN: 2155-6210

Journal of Biosensors & Bioelectronics
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Review Article

Management of Ductal Carcinoma In situ

Kefah Mokbel*

The London Breast Institute, The Princess Grace Hospital, London, UK

*Corresponding Author:
Kefah Mokbel
London Breast Institute
The Princess Grace Hospital, UK
Tel: 0044(0)2079082040
Fax: 0044(0)2079082275
E-mail: [email protected]

Received Date: September 13, 2011; Accepted Date: November 10, 2011; Published Date: November 17, 2011

Citation:Mokbel K (2011) Management of Ductal Carcinoma In situ. J Biosens Bioelectron S2:001. doi: 10.4172/2155-6210.S2-001

Copyright: © 2011 Mokbel K. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Ductal carcinoma in situ (DCIS) is a heterogeneous disease characterized by noninvasive clonal proliferation of malignant epithelial cells arising from the mammary ducts and terminal ductal-lobular units. Its reported incidence is rising due to the wide adoption of screening mammography and magnetic resonance imaging (MRI). The combination of nuclear grade and presence of necrosis is currently the best predictor of biological behavior. DCIS should be managed in the context of a multidisciplinary team. Local control depends upon adequate surgical clearance with margins of
at least 2mm. Sentinel lymph node biopsy (SLNB) is not routinely indicated and should be reserved for those with concurrent or recurrent invasive disease. SLNB can be considered in patients undergoing mastectomy (MX) and those with risk factors for invasion such as palpability, comedo morphology, necrosis or recurrent disease. Radiotherapy (RT) following breast conserving surgery (BCS) significantly reduces local recurrence (LR), particularly in those at high-risk. There remains a lack of level-1 evidence supporting the omission of adjuvant RT in selected low risk cases. Large, multi-centric or recurrent lesions (particularly in cases of prior RT) should be treated by MX with the opportunity for immediate reconstruction. Adjuvant Tamoxifen may reduce the risk of LR in selected cases with hormone sensitive disease. Further research is required to determine the role of contemporary RT regimes and endocrine therapies. Biological profiling and molecular analysis represent an opportunity to improve our understanding of the tumour biology of this condition and rationalise its treatment. Reliable identification of low-risk lesions could allow treatment to be less radical or safely omitted.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
 
In Association with
 
romanian
 
icamb2015
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords